´Ù¹ß°ñ¼öÁ¾¿¬±¸È¸ Update on MM 2024(ASH review) : 2024-02-03
±³À°ÀÏÀÚ : 2024-02-03
±³À°Àå¼Ò : ¼¼Á¾´ëÇб³ ´ë¾ç AI ¼¾ÅÍ 12Ãþ AI hall
±³À°ÁÖÁ¦ : Update on MM 2024(ASH review)
ÁÖÃÖ±â°ü : ´ëÇÑÇ÷¾×ÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : ´Ù¹ß°ñ¼öÁ¾¿¬±¸È¸
´ã´çÀÚ : ¼È¿Áø
¿¬¶ôó : 02-516-6581
À̸ÞÀÏ : kmmwp_office@naver.com
±³À°Á¾·ù : ³»°ú, Áø´Ü°Ë»çÀÇÇаú
Âü¼®¿¹»óÀÎ : 120¸í
Èñ¸ÁÆòÁ¡ : 5Á¡
Áö¿ª : ¼¿ïƯº°½Ã
±³À°½Ã°£ : 5 ½Ã°£ 0ºÐ
¼¼ºÎ¼ö°·á : 0¿ø
ºñ°í "Á¼® ¼ö Á¦ÇÑÀ¸·Î »çÀüµî·ÏÀÌ Á¶±â ¸¶°¨ µÉ ¼ö ÀÖÀ¸¸ç,
ÇöÀåµî·Ï Âü¼®ÀÌ ºÒ°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù."
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 02¿ù 03ÀÏ ¼¼Á¾´ëÇб³ ´ë¾ç AI ¼¾ÅÍ, 12Ãþ AI hall 09:30~09:55 Genomics and epigenomics of MM ±è¹Ì¿µ(¿ï»êÀÇ´ë)
±³À°½Ã°£ 02¿ù 03ÀÏ ¼¼Á¾´ëÇб³ ´ë¾ç AI ¼¾ÅÍ, 12Ãþ AI hall 09:55~10:20 Immune dysregulation in MM Á¶Çö¼ö(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 02¿ù 03ÀÏ ¼¼Á¾´ëÇб³ ´ë¾ç AI ¼¾ÅÍ, 12Ãþ AI hall 10:30~10:55 MGUS and smoldering MM À̸í¿ø(Ãæ³²ÀÇ´ë)
±³À°½Ã°£ 02¿ù 03ÀÏ ¼¼Á¾´ëÇб³ ´ë¾ç AI ¼¾ÅÍ, 12Ãþ AI hall 10:55~11:20 MRD and risk stratification ±èÇö¿µ(¼º±Õ°üÀÇ´ë)
±³À°½Ã°£ 02¿ù 03ÀÏ ¼¼Á¾´ëÇб³ ´ë¾ç AI ¼¾ÅÍ, 12Ãþ AI hall 11:30~12:20 Management of patients with myeloma-related bone disease Evangelos Terpos(National and Kapodistrian University of Athens)
±³À°½Ã°£ 02¿ù 03ÀÏ ¼¼Á¾´ëÇб³ ´ë¾ç AI ¼¾ÅÍ, 12Ãþ AI hall 13:10~13:40 Frontline therapy for transplant-eligible patients º¯ÀÚ¹Î(¼¿ïÀÇ´ë)
±³À°½Ã°£ 02¿ù 03ÀÏ ¼¼Á¾´ëÇб³ ´ë¾ç AI ¼¾ÅÍ, 12Ãþ AI hall 13:40~14:10 Frontline therapy for transplant-ineligible patients Á¤Á¾Çå(±¹¸³¾Ï¼¾ÅÍ)
±³À°½Ã°£ 02¿ù 03ÀÏ ¼¼Á¾´ëÇб³ ´ë¾ç AI ¼¾ÅÍ, 12Ãþ AI hall 14:20~14:50 Treatment for RRMM (I) CAR-T, ADC ±è´ÙÁ¤(°í½ÅÀÇ´ë)
±³À°½Ã°£ 02¿ù 03ÀÏ ¼¼Á¾´ëÇб³ ´ë¾ç AI ¼¾ÅÍ, 12Ãþ AI hall 14:50~15:20 Treatment for RRMM (II): BiTEs, Other ÀÌÁØÈ£(Áß¾ÓÀÇ´ë)
±³À°½Ã°£ 02¿ù 03ÀÏ ¼¼Á¾´ëÇб³ ´ë¾ç AI ¼¾ÅÍ, 12Ãþ AI hall 15:20~15:50 Rare diseases including Amyloidosis, POEMS and WM ¾ç½Â¾Æ(°¡Å縯ÀÇ´ë)